Natural immunity from a COVID-19 infection provides meaningful protection for at least several months, but it doesn’t last forever and doesn’t protect equally against all outcomes. The short answer: protection against reinfection starts declining noticeably after about 3 to 6 months, while protection against severe illness and hospitalization holds up significantly longer, persisting for at least 1 to 2 years in most people.
The longer answer depends on which part of the immune system you’re talking about, which variant you were infected with, and what you’re measuring: infection itself, hospitalization, or death.
Antibodies Fade First
After a COVID infection, your body produces antibodies that can neutralize the virus on contact. These are your first line of defense, and they’re also the first to decline. Antibodies in your blood (the kind that fight the virus once it’s already in your body) remain elevated for roughly 16 months after infection, though they begin dropping around the 6-month mark. Antibodies in your saliva and nasal passages, which are the ones that could block the virus before it takes hold in your airways, fade much faster. Research published in Frontiers in Immunology found that salivary antibodies had mostly fallen to baseline levels by 6 months post-infection.
This matters because it explains why reinfection becomes more likely over time even though your immune system still “remembers” the virus. The antibodies that patrol your nose and throat, where the virus first lands, are largely gone within half a year. That’s a big reason why people catch COVID more than once.
Memory Cells Last Much Longer
Antibodies are only part of the story. Your immune system also creates memory B cells and memory T cells, which are long-lived cells that can ramp up a new immune response if they encounter the virus again. These don’t prevent infection the way circulating antibodies do, but they’re the reason a second infection is typically less severe than the first.
About 95% of people tested retained immune memory at 6 months after infection, and over 90% still had functional T-cell memory at 6 to 8 months. Memory B cells actually continue to mature and improve between 1 and 6 months after infection, becoming better at recognizing the virus over time. For context, people who recovered from the original SARS outbreak in 2003 still had reactive memory T cells 17 years later. While SARS-CoV-2 hasn’t been around that long, this suggests cellular memory from COVID could persist for many years.
Imaging research from Science Translational Medicine has confirmed that activated T cells remain detectable in tissues throughout the body for up to 2 years after infection, including in the lungs, gut, and lymph nodes. This ongoing immune activity was present even in people who felt fully recovered and had no lingering symptoms.
Protection Against Severe Illness Holds Up
The practical question most people care about is whether a past infection will keep them out of the hospital. The evidence here is reassuring. A large study tracking outcomes over two years found that after surviving the first 6 months post-infection, previously infected individuals actually had lower mortality rates compared to those who had never been infected. This reduced risk persisted through at least two years of follow-up.
This pattern makes sense given what we know about memory cells. Even after antibodies decline and you become vulnerable to catching COVID again, your immune system can still mount a rapid, targeted response that prevents the virus from overwhelming your body. The protection against catching COVID fades; the protection against dying from it is far more durable.
Variants Change the Math Significantly
One of the biggest factors in how long natural immunity “lasts” is whether the next variant you encounter looks like the one that originally infected you. When Omicron emerged, it was different enough from earlier strains that protection from a pre-Omicron infection dropped to just 20 to 45% against reinfection. By contrast, protection from a previous Omicron infection against a new Omicron subvariant held up better, ranging from 50 to 90%.
This is why many people who went years without catching COVID during the earlier waves got infected once Omicron arrived. Their immune systems had been trained on a virus that looked meaningfully different from the one now circulating. Each new wave of subvariants continues to drift further from previous versions, which gradually erodes the effectiveness of immunity built from any single past infection.
Mild Cases Still Build Strong Immunity
You might assume that a worse infection would produce stronger, longer-lasting immunity, but the evidence doesn’t clearly support that. Research from Washington University School of Medicine found that people with mild COVID-19 developed durable, long-lasting antibody-producing cells in their bone marrow, the kind that can keep generating antibodies for years. Even people who had asymptomatic infections may develop lasting immune memory, though this hasn’t been as thoroughly studied.
The relationship between severity and immunity is complicated. Severe infections involve more virus in the body, which can stimulate a bigger immune response. But they also involve intense inflammation, which can actually impair the quality of that immune response. Researchers haven’t found a clear advantage to having been sicker.
Age Doesn’t Erase Natural Immunity
Older adults generally produce weaker immune responses to vaccines compared to younger people, which raised concerns that natural immunity might also fade faster with age. But research published in The Lancet Healthy Longevity found something encouraging: older adults who had recovered from a previous COVID infection generated robust, long-lived immune memory that was comparable to what younger adults produced. In a cohort that included residents over 80 years old, those with evidence of prior infection achieved nearly 100% viral neutralization after vaccination, matching the performance of much younger healthcare workers.
This suggests that while aging weakens the initial immune response to a vaccine, a prior infection can compensate for that gap, giving older adults a stronger foundation to build on.
Hybrid Immunity Offers an Extra Layer
Hybrid immunity, the combination of a past infection plus vaccination, generally provides broader and more durable protection than either one alone. A large population study from Estonia found that hybrid immunity reduced the risk of infection by about 39% compared to natural immunity alone during the Delta wave. However, that advantage largely disappeared once Omicron became dominant, suggesting that hybrid immunity also has limits against highly mutated variants.
Where hybrid immunity showed the clearest benefit was against hospitalization. COVID-related hospitalizations were extremely rare among people with hybrid immunity across the entire study period, regardless of which variant was circulating. If you’ve had COVID and are wondering whether vaccination still matters, this is the strongest argument: the combination keeps severe outcomes rare even when it can’t fully prevent reinfection.
The 90-Day Window
The CDC considers the first 90 days after an infection a period where interpreting a new positive test is difficult, since leftover viral material can trigger positive results without representing a true new infection. This 90-day window is a practical acknowledgment that most people retain enough protection in the first few months to make reinfection uncommon, though not impossible. After that window, a new positive test is more likely to represent a genuine reinfection, and the risk of one increases as months pass.
In practical terms, your strongest protection is in the first 3 to 6 months after infection. From 6 to 12 months, you’re increasingly vulnerable to catching COVID again, especially from a new variant, but your risk of severe illness remains low. Beyond a year, reinfection becomes fairly common, though the immune memory that protects against hospitalization and death appears to persist for at least 2 years based on current data.